Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports: a Prospective Randomized Controlled Trial

NCT04309240 is registered in ClinicalTrials.gov with LiuZhou People's Hospital as lead sponsor.

NCT NCT04309240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04309240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports: a Prospective Randomized Controlled Trial
Lead sponsor
LiuZhou People's Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
March 8, 2020
Completion date
March 8, 2022
Enrollment
204 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, rivaroxaban, thromboprophylaxis